[1] Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol, 2021,18(4):223-238. [2] Iwadare T, Kimura T, Kunimoto H,et al. Long-term pemafibrate treatment exhibits limited impact on body fat mass in patients with hypertriglyceridemia accompanying NAFLD. Front Endocrinol (Lausanne), 2024,15:1329294. [3] 尹曼,黄新娟,张荷,等. 代谢相关脂肪性肝病患者运动依从性的研究进展. 中华健康管理学杂志,2024,18(1):68-72. [4] Taha MM, Abdelghany AI, Draz RS. Lipidprofile response to electroacupuncture in non-alcoholic fatty liver patients with hyperlipidemia. J Acupunct Meridian Stud, 2021,14(1):21-26. [5] Liang M, Pan Y, Zhong T,et al. Effects of aerobic, resistance, and combined exercise on metabolic syndrome parameters and cardiovascular risk factors: a systematic review and network meta-analysis. Rev Cardiovasc Med, 2021,22(4):1523-1533. [6] 中华医学会肝病学分会.代谢相关(非酒精性)脂肪性肝病防治指南(2024年版).实用肝脏病杂志,2024,27(4): 494-510. [7] 中国成人血脂异常防治指南修订联合委员会. 中国成人血脂异常防治指南(2016年修订版). 中华全科医师杂志,2017,16(1):15-35. [8] Morishita A, Oura K, Takuma K,et al. Pemafibrate improves liver dysfunction and non-invasive surrogates for liver fibrosis in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: a multicenter study. Hepatol Int, 2023,17(3):606-614. [9] Hansen CD, Gram-Kampmann EM, Hansen JK, et al. Effect of calorie-unrestricted low-carbohydrate, high-fat diet versus high-carbohydrate, low-fat diet on type 2 diabetes and nonalcoholic fatty liver disease : A randomized controlled trial. Ann Intern Med, 2023,176(1):10-21. [10] Lu CW, Yang KC, Chi YC, et al. Adiponectin-leptin ratio for the early detection of lean non-alcoholic fatty liver disease independent of insulin resistance. Ann Med, 2023,55(1):634-642. [11] Nouri S, Navari M, Shafiee R, et al. The rs1862513 promoter variant of resistin gene influences susceptibility to nonalcoholic fatty liver disease. Rev Assoc Med Bras (1992), 2024,70(7):e20231537. [12] Damavandi N, Zeinali S. Association of xenobiotic-metabolizing enzymes (GSTM1 and GSTT 1), and pro-inflammatory cytokines (TNF-α and IL-6) genetic polymorphisms with non-alcoholic fatty liver disease. Mol Biol Rep, 2021,48(2):1225-1231. [13] 王芳,高晓霞,汪庆强. 黄连解毒汤联合益生菌制剂对非酒精性脂肪性肝炎患者中医症候积分和肠道菌群平衡的影响. 实用肝脏病杂志,2022,25(2):235-238. [14] Reddy A, Gatta PD, Mason S, et al. Adherence to a Mediterranean diet may improve serum adiponectin in adults with nonalcoholic fatty liver disease: The MEDINA randomized controlled trial. Nutr Res, 2023,119:98-108. [15] Bi Y, Yin B, Fan G, et al. Effects of acupoint therapy on nonalcoholic fatty liver disease: A systematic review and meta-analysis. Complement Ther Clin Pract, 2021,43:101376. [16] 梁惠卿,林立,刘垚昱,等. 皂术茵陈方对非酒精性脂肪性肝炎大鼠USP18/TAK1/NF-κB信号通路的影响. 中华中医药杂志,2023,38(10):4887-4890. [17] 刘凯利,张强,李军辉, 等. 柴胡人参药对通过调控胆汁酸代谢防治NAFLD的研究 .中华中医药学刊,2022,40(3):101-106+267. [18] Luo L, Zhang H, Chen W, et al. Angelica sinensis polysaccharide ameliorates nonalcoholic fatty liver disease via restoring estrogen-related receptor α expression in liver. Phytother Res, 2023,37(11):5407-5417. [19] Chen C, Yang L, Li M, et al. Study on the targeted regulation of Scutellaria baicalensis leaf on glutamine-glutamate metabolism and glutathione synthesis in the liver of D-gal ageing rats. J Pharm Pharmacol, 2023,75(9):1212-1224. [20] Yamada Y, Saito H, Araki M, et al. Wogonin, a compound inScutellaria baicalensis, activates ATF4-FGF21 signaling in mouse hepatocyte AML12 cells. Nutrients, 2022,14(19):3920. |